Millennium Management
GTBP icon

Millennium Management’s GT Biopharma GTBP Stock Holding History

Millennium Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-88
Closed -$16.8K – 6364
2023
Q4 		$16.8K Sell
88
-29
-25% -$5.3K ﹤0.01% 5662
2023
Q3 		$21.2K Sell
117
-196
-63% -$40.5K ﹤0.01% 5639
2023
Q2 		$73.3K Buy
313
+122
+64% +$31.6K ﹤0.01% 5397
2023
Q1 		$79K Buy
191
+15
+9% +$8.59K ﹤0.01% 5497
2022
Q4 		$118K Sell
176
-29
-14% -$36.2K ﹤0.01% 5519
2022
Q3 		$271K Sell
205
-121
-37% -$231K ﹤0.01% 5453
2022
Q2 		$730K Buy
+326
New +$618K ﹤0.01% 4660
2021
Q4 		– Sell
-46
Closed -$230K – 7020
2021
Q3 		$230K Buy
+46
New +$346K ﹤0.01% 6020
2021
Q2 		– Sell
-37
Closed -$191K – 6734
2021
Q1 		$191K Buy
+37
New +$162K ﹤0.01% 5510

Other funds holding GTBP

Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Millennium Management's GTBP Position: Q1 2024 in Review

Millennium Management sold out of GT Biopharma (GTBP) in Q1 2024, closing a stake of 88 shares — an estimated $16.8K sold.

Millennium Management first reported a position in GTBP in Q1 2021 and held it in 9 quarters. The position peaked at $730K in Q2 2022. 11 funds tracked by Wall St. Rank hold GTBP as of Q1 2024.

  • Millennium Management reported no remaining GT Biopharma position as of Q1 2024 after selling out during the quarter.
  • Millennium Management sold 88 GT Biopharma shares in Q1 2024, an estimated $16.8K.
  • Millennium Management first reported a position in GT Biopharma in Q1 2021 and held it in 9 quarters.
  • Millennium Management's GT Biopharma position peaked at $730K in Q2 2022.
  • 11 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2024.

Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.